Precision & Innovation

Mastering qPCR and dPCR for Advanced Diagnostics and Research

Noble Life Sciences presents a groundbreaking whitepaper on the transformative impact of quantitative PCR (qPCR) and digital PCR (dPCR) in life sciences research and diagnostics. This comprehensive guide outlines the precision and innovation behind these pivotal technologies, offering invaluable insights for industrial success.

DOWNLOAD OUR WHITEPAPER TO EXPLORE:

The principles and steps for mRNA expression and DNA quantification
Advanced fluorescent detection techniques and data analysis
The role of reference genes in standardizing results
Cutting-edge comparisons between qPCR and dPCR methods
Commercial instruments and their specifications for both technologies
Regulatory insights and the integration of dPCR in therapeutic research

Whether you're involved in biomarker discovery, pathogen detection, or the development of cell and gene therapies, our whitepaper is your key to elevating your research and development efforts.

Download the Whitepaper

More Noble Whitepapers & Resources

See other whitepapers, webinars, and resources from Noble Life Sciences experts to advance your programs.

Discover more >

Built to Advance Your Noble Research

See what our clients say about working with Noble Life Sciences.

“Noble has been instrumental in enabling the accelerated testing of Jaguar’s preclinical gene therapy program. We are impressed by Noble’s experience and unparalleled support. As a leader in drug, device, and vaccine development, Noble appreciates the significance of Jaguar’s mission to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases.”

“Noble has been a strong partner for us, helping to accelerate testing of our synthetic biologics. Our Amicidins are new and innovative, requiring special attention to local application and performance in models. Noble has been flexible and agile in meeting our needs with high-quality work. We are pleased with the part Noble has played in advancing our programs, as we look to prevent and treat life-threatening infections in surgery and trauma.”

– Director, Preclinical Development

“The Noble team has done an outstanding job assisting us and accommodating our every need. Their guidance has been accurate, and their work has been excellent. They are experts in the field and are up-to-date with industry standards. We are grateful for everything they have done to help us advance the development of our regenerative medicine therapies.”

– CEO, Britecyte, Inc.

“We have been extremely impressed by Noble’s flexibility and dedication to quality. They have consistently gone above and beyond to meet our needs and have been a valuable partner in our growth. Their customer service is unmatched and we have enjoyed working with them on multiple projects. We are grateful for their partnership and look forward to continuing to work together in the future.”

– Co-Founder, DEKA BioSciences

“We needed a local CRO that is flexible and fast-paced to support our AAV gene therapy research and preclinical programs. Luckily, we found Noble who exceeded our expectations. Our teams work seamlessly as if they are an extension of our lab and provided necessary resources to advance our research in the most cost-effective way.”

– VP, Target Discovery & Early Portfolio